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Ivermectin is the drug of choice in the treatment of onchocerciasis, and has been proven to be highly 
effective against Strongyloides stercoralis. This study compares ivermectin’s efficacy and safety with 
that of thiabendazole, an established drug of choice for strongyloidiasis, in 252 confirmed cases of 
uncomplicated human intestinal strongyloidiasis. Subjects were administered orally with ivermectin 
(200 µg/kg) in a single dose or thiabendazole, 25 mg/kg, twice daily (50mg/kg/day) for 3 consecutive 
days. Stools were parasitologically examined 7, 21 and 30 days after treatment. Only 18 of 113 and 22 
of 103 ivermectin- and thiabendazole-treated subjects, respectively, had stools positive for larvae 30 
days post-treatment. This indicates parasitological cure rates of 84.07% and 78.64% for ivermectin 
and thiabendazole, respectively. Ivermectin was not significantly more effective than thiabendazole (P 
< 0.05). There was considerable reduction in parasite output in parasitologically uncured subjects 
with mean of 81% in ivermectin-treated and 75% in thiabendazole-treated groups, respectively. 
Clinical adverse reactions were mild and transient in subjects treated with ivermectin, while they 
varied from mild to severe in those treated with thiabendazole. Single-dose ivermectin provides 
efficacy comparable with standard, multiple-dose thiabendazole, with a much reduced incidence of 
adverse effects and consequently better patient compliance.  
 





Strongyloides stercoralis is an intestinal nematode 
parasite found chiefly in tropical and subtropical regions 
of the world, although endemic regions abound in 
southeast USA, Japan and south Europe (Datry et al., 
1994). Infections with this parasite are usually of a 
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the parasite (Grove, 1982). According to Genta (1989), 
severe disseminated disease may occur in 
immunocompromised and untreated individuals. 
Chemotherapy is advocated and considered an 
effective control measure for the reduction of morbidity 
resulting from intestinal nematode infection (Savioli et al., 
1992; Warren et al., 1993). The current drug of choice for 
strongyloidiasis is the benzimidazole compound, 
thiabendazole, introduced into human medicine three 
decades ago. Therapy with this drug is  however,  fraught  
  




with a number of disadvantages. It is not always curative 
(Most, 1984) and some investigators have suggested that 
it merely reduces larval production (Grove, 1982). 
Treatment often requires multiple doses (at least 3 
consecutive days of treatment) and is frequently 
associated with considerable adverse effects, particularly 
in the gastro-intestinal and neuropsychiatric systems 
(Grove, 1982, 1989; Most, 1984), thus reducing 
compliance. 
Ivermectin, a semi-synthetic macrocyclic lactone 
derivative of Avermectin B, has gained wide acceptability 
as the drug of choice in the treatment of human 
onchocerciasis. Single oral doses of ivermectin have 
been found to be highly effective and well tolerated 
(Greene et al., 1985; Richard-Lenoble, 1998). It has also 
been reported to have a wide spectrum of activity against 
many nematodes and ectoparasites of man and domestic 
animals, including Strongyloides westeri and Strongylus 
vulgaris (Goldsmith, 1988; Campbell, 1989). Data from 
non-comparative (Freedman et al., 1989; Scaglia et al., 
1990; Testa et al., 1990) and comparative studies with 
other drugs (Datry et al., 1994; Gann et al., 1994; Marti et 
al., 1996) indicate that the drug is well tolerated and 
highly effective in the treatment of S. stercoralis infections 
in man. The results presented here are those of a study 
comparing the efficacy and safety of single-dose 




MATERIALS AND METHODS 
 
Study population and Choice of subjects 
 
The study was carried out in collaboration with the Primary Health 
Care Unit of the Yewa South Local Government area of Ogun 
State, Nigeria. The study population comprised 274 subjects, aged 
5 to 66 years, with uncomplicated intestinal strongyloidiasis and 
whose stools were positive for S. stercoralis larvae during a larger 
survey on intestinal helminths (unpublished data). Prior to 
participation, a full medical history was taken from each subject, 
while a physical examination was conducted by the physician (A.O. 
Adenusi). 
Subjects qualified for participation in the study if they had not 
received any form of anti-filarial therapy and any other anthelmintic 
treatment in the 6 months and 72 h respectively, preceding the 
study. Only subjects with no allergic diatheses, disseminated 
strongyloidiasis, severe renal, hepatic, haematological 
(haemoglobin level under 5 g/dL) or cardiovascular functions 
participated in the study. Potentially childbearing women not using 
contraceptives and subjects in which the parasite was detected in 
stool samples more than 30 days before commencement of the 
study were excluded. Subjects were educated on the objectives of 
the study and the attendant benefits to them. Only those who gave 
informed oral consent (parents, if subjects were children) 





Following informed oral consent and before treatment, each 





plastic container and asked to bring a fresh stool sample the 
following day (pre-treatment stool sample). Each stool sample was 
parasitologically examined quantitatively in the laboratory for the 
larvae of S. stercoralis, using the modified Baermann concentration 
technique (WHO, 1981). The immediate examination of the freshly 
passed stool samples enabled detection of the rhabditiform larvae 
of S. stercoralis, which were recognised by their characteristically 





Subjects were assigned to either ivermectin- or thiabendazole-
treatment group using a randomised list for the sequential allocation 
of the drugs, prepared in advance. They were weighed and those in 
the former group administered with single dose, 200 µg/kg body 
weight ivermectin (Mectizan, M.S.D.). They had fasted for 6 h 
before and were also asked to fast for 2 h after drug intake, so as to 
ensure satisfactory absorption. Thiabendazole (Mintezol, M.S.D.) 
was administered as a twice-daily oral dose (each 25 mg/kg body 
weight) with meals for 3 consecutive days, up to a maximum daily 
dose of 3 g for patients over 60 kg. Drug intake was under personal 
supervision. All treated subjects were instructed to report any new 
signs and symptoms (adverse effects), following drug administration 
to medical assistants. 
 
 
Evaluation of drug safety 
 
Clinical adverse effects of either drug were investigated through 
voluntary spontaneous complaints by subjects and also by 
interviews conducted using a standard questionnaire based on the 
common adverse effects of either drug reported in the literature. All 
these were done within 7 days post-treatment. 
 
 
Evaluation of drug efficacy 
 
Drug efficacy was evaluated on days 7, 21 and 30 post-treatment 
when follow-up stool samples were collected and examined, using 
the same procedures as in the pre-treatment. Each subject served 
as his or her own control as both pre- and post-treatment stool 
sample parasite counts were compared in each subject. In this 
study, a subject was considered parasitologically cured, if all 3 post-
treatment stool samples tested negative for larvae of S. stercoralis. 
All subjects who did not provide all 3 follow-up stool samples (on 
days 7, 21 and 30 post-treatment) were excluded from the analysis 
of drug efficacy. Analysis of drug efficacy was carried out using the 
chi-square test while the reduction in mean parasite output (in 
parasitologically uncured subjects) was analysed using the t-test 





Of the 274 subjects with S. stercoralis larvae in their stool 
samples, only 252 were eligible for participation in the 
trial, 22 having been excluded for medical reasons. Of 
the 252, 21 had incomplete treatments, while 15 had 
incomplete follow-ups (i.e. did not submit all 3 post-
treatment stool samples). Only the 216 subjects with 
complete treatment and follow-ups were used for 
evaluation of drug efficacy (i.e. calculation of cure rates 
and parasite load reduction). Of these, 113 were of the 
ivermectin    group,    while    103    were    treated     with  















Treatment group  
Ivermectin Thiabendazole Total 
No. eligible for participation in trial 126 126 252 
No. with incomplete treatment 4 17 21 
No. evaluated for adverse effects of drug 122 109 231 
No. evaluated for drug efficacy  113 103 216 
Males 59 55 114 





                                Table 2. Results by treatment group of follow-up stool examinations, using the Baermann technique. 
 
Days post-treatment Treatment 
group 
7 21 30 
Cure % reduction of 
mean parasite 
output (range) 
Ivermectin 107/122 98/116 95/113 84.07 81 (77-86) 
Thiabendazole 85/109 81/105 81/103 78.64 75 (69-81)     
 
Note: 
__ data shown are no. of subjects negative for larvae/no. of subjects tested. 
__ declines in no. of samples tested with days reflect loss of subjects due to follow-up. 
__ declines in no. of samples negative for larvae with days reflect treatment failure and loss of 
    subjects due to follow-up. 
 
 
thiabendazole for 3 consecutive days (Table 1). Both 
treatment groups were comparable in parasite/worm 
burdens, age and sex. 
Table 2 shows cure rates and percent larval reduction 
following treatment with either ivermectin or 
thiabendazole. Of the 113 ivermectin-treated subjects, 
there was parasitological cure in 84.07%, while 78.64% 
of the thiabendazole-treated subjects were 
parasitologically cured, 30 days after treatment. The 
observed higher cure rate with ivermectin was however, 
not significant (P < 0.05). Treatment failures were 
detected in 13 of the 18 parasitologically uncured 
ivermectin-treated subjects on day 7 post-treatment, and 
in another 5 on day 21. Out of the 22 parasitologically 
uncured thiabendazole-treated subjects, treatment 
failures were detected in 19 on day 7 post-treatment and 
in 3 on day 21. Mean parasite (larval) counts in 
parasitologically uncured subjects declined by 81% 
(range, 77 to 86%) among the 18 parasitologically 
uncured ivermectin-treated subjects, while it declined by 
75% (range, 69 to 81%) in the thiabendazole group. The 
difference in mean reductions between the two groups 
was also not significant (P < 0.05).  
At baseline (before treatment), signs and symptoms 
such as epigastric pain, urticaria and diarrhoea were 
recorded in subjects. They were possibly associated with 
strongyloidiasis as there were significant declines in all 
these symptoms, 21 days after treatment, even in 
parasitologically uncured subjects. There was no 
difference in the resolution of symptoms for the two 
treatment regimens. 
Of the 231 subjects evaluated for adverse effects of 
drug treatments, 48.48% experienced one or more side 
effects of  either  medication,  31.15%  in  the  ivermectin- 
 Males Females Totals 
Number positive for S. stercoralis larvae 141 133 274 
Number excluded from study 12 10 22 








treated subjects and 67.89% in the thiabendazole-treated 
group (difference significant). Over 95% of the adverse 
effects were reported within 3 days after treatment.  
Constipation and fever were reported only after 
ivermectin treatment, while malaise, anorexia, abdominal 
pain and disorientation were reported only with 
thiabendazole medication. Nausea, fatigue and dizziness 
were recorded significantly more often after 
thiabendazole medication (Table 3).   
Most of the adverse reactions after medication with 
ivermectin were considered mild and transient, as the 
subjects though aware of these reactions easily tolerated 
them and did not last for more than 24 to 48 h. Adverse 
reactions varied from mild to severe and lasted 1 to 7 
days in those treated with thiabendazole. Twenty two of 
the subjects treated with thiabendazole, including all 16 
with disorientation were sufficiently incapacitated to be 




Table 3. Number of subjects developing one or more new signs 






Constipation 0 7* 
Nausea 49* 5 
Fatigue 54* 16 
Malaise 21* 0 
Dizziness 28* 6 
Anorexia 39* 0 
Abdominal pain 6* 0 
Fever 0 8* 
Headache 7 11 
Disorientation 16* 0 
 
n = number of subjects evaluated for adverse effects after treatment. 





At present, the therapeutic arsenal available for the 
treatment of strongyloidiasis includes thiabendazole and 
its alternative, albendazole. The unsatisfactory efficacy of 
these two drugs and the frequent and considerable 
adverse reactions associated with thiabendazole therapy 
have however, prompted the need for better therapeutic 
alternatives. 
The cure rate recorded for ivermectin in the present 
study is within the range reported by previous workers 
using ivermectin in similar dosages, either in non-
comparative studies (Freedman et al., 1989; Naquira et 





(Datry et al., 1994; Gann et al., 1994; Marti et al., 1996) 
in the treatment of uncomplicated, human 
strongyloidiasis. Similarly, the cure rate recorded for 
thiabendazole in the present study fall within those 
reported by previous workers (Nauenberg et al., 1970; 
Grove, 1982), although the drug has been reported not to 
be curative (Most, 1984). Although ivermectin recorded a 
higher cure rate than thiabendazole in the present study, 
this difference was not significant. Gann et al. (1994) 
found ivermectin to be at least as effective as 
thiabendazole in the treatment of uncomplicated 
strongyloidiasis. 
Inspite of the failure of either drug to cure infection (18 
subjects in ivermectin- and 22 subjects in thiabendazole-
treated groups), there was still some level of reduction in 
parasite counts after treatment. The failure of either drug 
to completely eradicate the parasite in some of these 
subjects is surprising as some of them, even had lesser 
parasite counts before treatment than some 
parasitologically cured patients. Thus, non-cure in these 
patients could not be attributed to heavy worm burden 
(parasite counts). These treatment failures 
notwithstanding, the results of the present study are 
reliably ensured by the one-month follow-up of patients 
and the effective use of the Baermann concentrations. 
The clinical signs and symptoms recorded at baseline (at 
the start of the trial and before drug treatments) have 
been reported previously as being associated with 
strongyloidiasis (Grove, 1989; Gann et al., 1994). The 
resolution of these signs and symptoms after either 
medication, even in parasitologically uncured subjects, 
indicates that they were associated with infection; this 
decline perhaps due to a decrease in worm burdens.  
Clinical adverse reactions encountered in the present 
study were as reported in previous studies where similar 
dosage regimens of ivermectin (Freedman et al., 1989; 
Naquira et al., 1989; Datry et al., 1994) or thiabendazole 
(Grove, 1982, 1989; Gann et al., 1994) were employed. 
Treatment with thiabendazole was associated with a 
significantly higher rate of adverse effects than was with 
ivermectin, which appeared to be better tolerated. Severe 
side effects including disorientation, which interfered with 
the normal daily activities of the subjects, were reported 
only after thiabendazole medication.  
The results of this study have further demonstrated and 
confirmed previous reports on the efficacy and relatively 
good safety of ivermectin in the treatment of 
uncomplicated strongyloidiasis in man (Freedman et al., 
1989; Naquira et al., 1989; Scaglia et al., 1990; Datry et 
al., 1994). 
Ivermectin is effective against both larval and adult 
stages of S. stercoralis (Liu and Weller, 1993). 
Observations in previous studies of ivermectin use in 
humans indicate that the drug can be effective in patients 
who have not responded to repeated courses of 
thiabendazole (Wijesundera and Sanmuganathan, 1992; 






Ideally, a very good anthelmintic for the treatment of 
gastrointestinal helminthiasis and in particular 
strongyloidiasis should be very effective in single dose 
regimens. Treatment of S. stercoralis infection with 
thiabendazole normally requires multiple doses in order 
to achieve optimum results, which is often associated 
with mild to severe toxicity. Due to the close monitoring of 
subjects, compliance with medication in the present study 
was believed to be excellent. In clinical practice however, 
many patients would be unwilling to complete the 
prescribed 3-day course of thiabendazole. The potency 
and safety of single-dose regimen of ivermectin against 
S. stercoralis infection as reported here as well as in 
previous studies renders more aggressive, multiple dose 
regimens as in the case with thiabendazole unnecessary. 
Campbell et al. (1983) have reported a wide margin of 
safety for ivermectin in cattle and dogs, as there were no 
toxicities associated with the administration of 10 to 30 
times the dose employed in this study. 
The presently reported efficacy of ivermectin, the 
advantage of a single-dose treatment and given the low 
frequency of mild adverse effects observed with 
ivermectin compared with thiabendazole, we conclude 
that single-dose (200 µg/kg body weight) ivermectin is a 
better treatment regimen and should become the 
treatment of choice for uncomplicated strongyloidiasis, 
especially in a developing country including Nigeria, 
where patient compliance with the multiple-dose/day 
regimen of thiabendazole is difficult and where 
concurrent onchocerciasis may also be endemic. Our 
results open the opportunity to evaluate in large-scale 
studies, whether ivermectin has any potential value in the 
treatment of chronic, gastrointestinal strongyloidiasis as 
well as complicated hyperinvasive strongyloidiasis in 
immunocompromised individuals. This is with a view to 
determining its potentiality as a recommended treatment 
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